Related Experiment Videos
Flutamide-induced liver injury: a case report
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|January 1, 1999
Summary
Flutamide, used for prostate cancer, can cause liver injury. Regular monitoring of liver function is crucial for patients on flutamide therapy.
Area of Science:
- Hepatology
- Pharmacology
- Oncology
Background:
- Flutamide is a nonsteroidal antiandrogen prescribed for prostate cancer.
- Hepatotoxicity associated with flutamide has been documented in Western countries.
- Early detection and management of drug-induced liver injury (DILI) are critical.
Observation:
- A 72-year-old male patient developed malaise, jaundice, and elevated liver enzymes after six months of flutamide treatment.
- The patient had no prior liver disease or concurrent medications.
- Liver biopsy confirmed pericentral and bridging hepatic necrosis.
Findings:
- Flutamide therapy was linked to significant elevations in ALT (1,035 U/l) and AST (745 U/l), and bilirubin (7.0 mg/dl).
- Viral hepatitis and autoimmune markers were negative, ruling out other causes.
- Causality assessment confirmed flutamide as the cause of drug-induced liver injury.
Implications:
- This case highlights the importance of vigilant liver function monitoring in patients receiving flutamide.
- Prompt discontinuation of flutamide is essential upon suspicion of DILI to prevent disease progression.
- Awareness of flutamide-induced hepatotoxicity is vital for clinicians managing prostate cancer patients.